How Pfizer Comirnaty Works and Where It Fits Today

Pfizer Comirnaty is an mRNA COVID-19 vaccine used to help prevent serious illness. Here is how it works, how it is used in the US, and what to know now.

Pfizer Comirnaty is an mRNA COVID-19 vaccine that received the first full FDA approval for a COVID-19 vaccine in the US in August 2021FDA, 08/23/2021CDC, 09/27/2023.

Updated: 05/17/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

At a Glance

• Product: Pfizer Comirnaty
• Category: mRNA COVID-19 vaccine
• Brand/Manufacturer: Pfizer and BioNTech
• Main Use Cases: Prevention of symptomatic COVID-19
• Availability: Prescription vaccine in the United States
• Key Markets: United States, European Union and other regions

What Pfizer Comirnaty Is and How It Works

Pfizer Comirnaty is a prescription mRNA vaccine used to help prevent COVID-19, the respiratory illness caused by SARS-CoV-2FDA, 09/11/2023CDC, 09/27/2023.

The vaccine uses a small piece of messenger RNA that gives cells instructions to make a harmless version of the coronavirus spike protein. The immune system then learns to recognize that protein and prepares a response for future exposureCDC, 01/11/2022FDA, 10/19/2023.

The mRNA in Comirnaty does not enter the cell nucleus and does not change a person's DNA, according to US health authoritiesCDC, 09/29/2023FDA, 01/31/2024.

Why Pfizer Comirnaty Matters for Consumers and Industry

Pfizer Comirnaty is one of several COVID-19 vaccines used to reduce the risk of severe disease, hospitalization and death from COVID-19, according to US public health guidanceCDC, 10/03/2023HHS, 01/08/2024.

For US consumers, Comirnaty is part of updated vaccination campaigns that focus on higher-risk groups, including older adults and people with certain medical conditions, to help lower the impact of respiratory virus seasonsCDC, 09/12/2023NFID, 02/06/2024.

For healthcare providers and employers, reliable COVID-19 vaccination tools, including Comirnaty, help support workplace continuity and reduce strain on clinics during surges, according to US health agenciesCDC, 03/01/2024OSHA, 12/15/2023.

Pfizer Comirnaty in the US and Global Market

In the United States, updated formulations of Pfizer Comirnaty are part of the COVID-19 vaccines recommended for eligible age groups, alongside other brands such as Moderna and NovavaxCDC, 09/27/2023FDA, 09/11/2023.

Globally, Comirnaty is supplied to many countries through national health systems and procurement programs, with oversight from regulators such as the European Medicines Agency and othersEMA, 01/15/2024WHO, 09/27/2023.

US regulators such as FDA and CDC continue to monitor the safety and effectiveness of Comirnaty through surveillance systems and advisory committee reviewsFDA, 02/02/2024CDC, 11/09/2023.

• Type: mRNA COVID-19 vaccine for prevention of COVID-19 in eligible age groups.
• Technology: Uses lipid nanoparticle delivery of mRNA that encodes spike protein.
• Setting: Administered by trained professionals in clinics, pharmacies and other sites.

Frequently Asked Questions About Pfizer Comirnaty

Who can receive Pfizer Comirnaty in the US?
Age indications and dosing schedules for Comirnaty vary by formulation and age group and are set out in FDA authorization documents and CDC guidanceCDC, 10/03/2023FDA, 09/11/2023.

How is Pfizer Comirnaty given?
The vaccine is given as an intramuscular injection, usually in the upper arm, by a trained healthcare professional, following the schedule specified in the product labelingFDA, 09/11/2023CDC, 10/06/2023.

Does Pfizer Comirnaty replace earlier Pfizer COVID-19 vaccines?
Updated Comirnaty formulations are used in current US vaccination programs in place of earlier Pfizer COVID-19 vaccine versions, according to FDA and CDCFDA, 09/11/2023CDC, 09/27/2023.

Pfizer is the pharmaceutical company that commercializes Comirnaty in partnership with BioNTech, which helped develop the underlying mRNA technology and platform.

Pfizer Inc. is listed on the New York Stock Exchange under the ticker PFE and issues shares under ISIN US7170811035 for global investors.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.